ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer

New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC).Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news